IOVA - Iovance Biotherapeutics, Inc. So'nggi... | Finranks

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance's revenue rose 66% last quarter due to strong demand for Amtagvi. The company also cut its losses by nearly 60%.

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

IOVA Q2 Earnings Beat, Stock Jumps 43% on Strong Amtagvi Uptake

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

Does Iovance Biotherapeutics (IOVA) Have the Potential to Rally 28.02% as Wall Street Analysts Expect?

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Iovance Biotherapeutics Q2 Earnings Call Highlights

Iovance Biotherapeutics Q2 Earnings Call Highlights

Iovance Biotherapeutics NASDAQ: IOVA reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic cancers.

Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September

Iovance: Stock Soars On Q2 Earnings - Critical Data In Melanoma, NSCLC Due September

Iovance Biotherapeutics is rated a buy, driven by strong Q2 results, surging Amtagvi sales, and promising pipeline catalysts. Q2 product revenues reached $99M, 10% above management guidance, with gross margin at 56% and a net loss of $(47.3m), beating consensus. IOVA's pipeline includes frontline melanoma and NSCLC, with key data presentations at ESMO and a BLA submission for NSCLC planned next year.

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (IOVA) Q2 2026 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.33 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas SAN CARLOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates.